Pegcetacoplan acetate is a pegylated complement C3 inhibitor peptide. Pegcetacoplan acetate acts by binding with complement component 3 (C3) and its activation fragment C3b. Pegcetacoplan acetate can be used for the research of complement-mediated diseases, including age-related macular degeneration, C3 glomerulopat, Geographic atrop (GA) and autoimmune haemolytic anaemia.
References:
[1]. David S Liao, et al. Complement C3 Inhibitor Pegcetacoplan for Geographic Atrop Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial. Ophthalmology. 2020 Feb;127(2):186-195.
[2]. Sheridan M Hoy, et al. Pegcetacoplan: First Approval. Drugs. 2021 Aug;81(12):1423-1430.